https://doi.org/10.4081/reumatismo.2018.1075
The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity
Accepted: 17 May 2018
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Based on the recent evidence of association between hyperprolactinemia and systemic lupus erythematosus disease activity (SLEDAI), a study was conducted to analyze the association of hyperprolactinemia with lupus nephritis disease activity. In this cross-sectional study, the analysis was conducted on SLE patients who visited the University Kebangsaan Malaysia Medical Centre (UKMMC) Nephrology Clinic from August 2015 till February 2016. The disease activity was measured using the SLEDAI score, with more than 4 indicating active lupus nephritis. Basal resting prolactin level was analyzed in 43 patients with lupus nephritis, in 27.9% of them had raised serum prolactin. The median of serum prolactin level at 0 minutes was 19.91 ng/mL (IQR: 15.95-22.65 ng/ mL) for active lupus nephritis, which was significantly higher compared to the median of serum prolactin level of 14.34 ng/mL (IQR: 11.09-18.70 ng/mL) for patients in remission (p=0.014). The serum prolactin level positively correlated with SLEDAI (rhos: 0.449, p=0.003) and the UPCI level in lupus nephritis patients (rhos: 0.241, p=0.032). The results were reproduced when the serum prolactin was repeated after 30 minutes. However, the serum prolactin levels at 0 minutes were higher than those taken after 30 minutes (p=0.001). An assessment of serum IL-6 levels found that the active lupus nephritis patients had a higher median level of 65.91 pg/ mL (IQR: 21.96-146.14 pg/mL) compared to the in-remission level of 15.84 pg/mL (IQR: 8.38-92.84 pg/mL), (p=0.039). Further correlation analysis revealed that there was no statistical correlation between the interleukin (IL)-6 levels with serum prolactin, SLEDAI and other lupus nephritis parameters. An ROC curve analysis of serum prolactin at 0 minutes and serum prolactin after 30 minutes and IL-6 levels for prediction of SLE disease activity provided the cutoff value of serum prolactin at 0 minutes, which was 14.63 ng/mL with a sensitivity of 91.7% and specificity of 58.1% and AUC of 0.74 (p=0.015). This study concurred with the previous findings that stated that hyperprolactinemia is prevalent in SLE patients and correlated with clinical disease activity and UPCI level. The baseline of the fasting serum prolactin level was found to be a sensitive biomarker for the evaluation of lupus nephritis disease activity.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- G. Tansir, P. Kumar, A. Pius, S.K. Sunny, M. Soneja, Pseudo-pseudo Meigs’ syndrome: a rare presentation of systemic lupus erythematosus , Reumatismo: Vol. 71 No. 2 (2019)
- M. Benucci, A. Damiani, F. Li Gobbi, V. Grossi, M. Infantino, A. Arena, M. Manfredi, Jaccoud’s arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment , Reumatismo: Vol. 69 No. 2 (2017)
- M. Govoni, N. Rizzo, G. Castellino, M. Padovan, F. Trotta, Neuropsychiatric systemic lupus erythematosus: where are we now? , Reumatismo: Vol. 57 No. 4 (2005)
- L. Cantarini, D. Rigante, M.G. Brizi, G.D. Sebastiani, O.M. Lucherini, M. Galeazzi, B. Frediani, The laboratory approach in the diagnosis of systemic autoinflammatory diseases , Reumatismo: Vol. 63 No. 2 (2011)
- F. Zare, M. Dehghan-Manshadi, A. Mirshafiey, The signal transducer and activator of transcription factors lodge in immunopathogenesis of rheumatoid arthritis , Reumatismo: Vol. 67 No. 4 (2015)
- M. Muratore, L. Quarta, L. Raho, D. Costanza, S. Frisenda, F. Calcagnile, A. Grimaldi, E. Quarta, D. Carati, M. Guido, A. Zizza, G. Alessandrini, Management of cutaneous discomfort in patients with scleroderma: a clinical trial , Reumatismo: Vol. 65 No. 5 (2013)
- B. Ruaro, A. Sulli, V. Smith, C. Pizzorni, S. Paolino, E. Alessandri, M. Cutolo, Microvascular damage evaluation in systemic sclerosis: the role of nailfold videocapillaroscopy and laser techniques , Reumatismo: Vol. 69 No. 4 (2017)
- T. Borges, A. Barbosa, S. Silva, Adult-onset systemic autoinflammatory disorders: a clinical approach , Reumatismo: Vol. 71 No. 4 (2019)
- E. Pigatto, D. Peluso, E. Zanatta, P. Polito, P. Miatton, K. Bourji, L. P. Badano, L. Punzi, F. Cozzi, Evaluation of right ventricular function performed by 3d-echocardiography in scleroderma patients , Reumatismo: Vol. 66 No. 4 (2014)
- M. S. Dag, I. H. Turkbeyler, Z. A. Ozturk, B. Kısacık, E. Tutar, A. Kadayıfçı, Cytomegalovirus ileocolitis in a rheumatoid arthritis patient: case report and literature review , Reumatismo: Vol. 67 No. 1 (2015)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
You may also start an advanced similarity search for this article.
